Samrat Pharmachem
214.00
-4.90(-2.24%)
Market Cap₹66.09 Cr
PE Ratio-40.39
IndustryHealthcare
Company Performance:
1D-2.24%
1M+5.84%
6M-27.02%
1Y-47.82%
5Y+14.47%
View Company Insightsright
More news about Samrat Pharmachem
15Nov 25
Samrat Pharmachem Reports Q2 FY26 Loss Despite Revenue Growth
Samrat Pharmachem Limited, a pharmaceutical chemicals manufacturer, released Q2 FY26 results ending September 30, 2025. Revenue increased by 10% to Rs. 7,887.03 lakhs, but the company reported a net loss of Rs. 58.73 lakhs. For the half-year, losses widened to Rs. 81.62 lakhs compared to a profit of Rs. 472.66 lakhs in the previous year. The half-year EPS stood at negative Rs. 2.64. The company continues to operate in a single business segment of pharmaceutical chemicals manufacturing.
 no imag found
25Jul 25
Samrat Pharmachem Reappoints Key Executives, Maintaining Family Leadership
Samrat Pharmachem Limited has announced the reappointment of three key executives for five-year terms, effective April 1, 2026, subject to shareholder approval. Lalit Mehta (88) will continue as Chairman & Managing Director, Rajesh Mehta (61) as Executive Director, and Megh Mehta (32) as Executive Director. The reappointments aim to maintain leadership continuity and leverage their extensive industry experience. The board will consist of seven directors, including three executive directors and four independent non-executive directors, balancing family leadership with independent oversight.
 no imag found
Samrat Pharmachem
214.00
-4.90
(-2.24%)
1 Year Returns:-47.82%
Industry Peers
Sun Pharmaceutical
1,620.40
(-3.55%)
Divis Laboratories
6,361.50
(-0.27%)
Torrent Pharmaceuticals
4,117.20
(-0.72%)
Dr Reddys Laboratories
1,317.10
(-1.04%)
Lupin
2,296.10
(-1.93%)
Cipla
1,295.00
(-0.83%)
Mankind Pharma
2,267.40
(-1.11%)
Zydus Life Science
927.40
(-2.00%)
Aurobindo Pharma
1,413.80
(-1.50%)
Glenmark Pharmaceuticals
2,299.50
(-1.52%)